Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fengyinhe Holdings | Hong Kong | Financial | Investment Banking & Investment Services | 117.5% | HK$271.38M | 0.9x | -0.19 | HK$0.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Everest Med | Hong Kong | Healthcare | Pharmaceuticals | 79.4% | HK$2.44B | -6.2x | HK$38.80 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
China Investment and Finance | Hong Kong | Financial | Investment Banking & Investment Services | 74.5% | HK$330.08M | -19.5x | -0.29 | HK$0.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OSL | Hong Kong | Technology | Financial Technology (Fintech) & Infrastructure | 68.7% | HK$4.95B | -21.9x | -0.59 | HK$8 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -16.9% Downside | Upgrade to Pro+ | |
Dynamic | Hong Kong | Real Estate | Real Estate Operations | 29.9% | HK$2.54B | 0.5x | 0 | HK$10.74 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | 28.7% | HK$2.76B | -180x | -1.65 | HK$4.51 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orient Securities Int | Hong Kong | Financial | Banking Services | 0% | HK$19.49M | 6.9x | 0.02 | HK$0.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sunwah Kingsway Capital | Hong Kong | Financial | Investment Banking & Investment Services | -1.3% | HK$171.98M | -3x | -0.11 | HK$0.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Yinsheng Digifavor | Hong Kong | Technology | Telecommunications Services | -1.7% | HK$1.12B | 28.5x | 0.16 | HK$2.71 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sands China | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -4% | HK$145.03B | 17.6x | 0.07 | HK$17.94 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.3% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | -5.7% | HK$12.15B | -30.5x | -0.52 | HK$39.60 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.5% Upside | Upgrade to Pro+ | |
Pinestone Capital | Hong Kong | Financial | Investment Banking & Investment Services | -8.5% | HK$61.99M | -4.8x | -0.05 | HK$0.22 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MGM China Holdings | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -9.5% | HK$39.29B | 8.8x | 0.03 | HK$10.42 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.7% Upside | Upgrade to Pro+ | |
Tong Tong AI Social | Hong Kong | Financial | Banking Services | -10.8% | HK$1.51B | 11.7x | 0.03 | HK$0.29 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Merchants China Direct | Hong Kong | Financial | Investment Banking & Investment Services | -11.4% | HK$2.05B | 173.1x | 1.54 | HK$13.50 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zhaoke Ophthalmology | Hong Kong | Healthcare | Pharmaceuticals | -13.2% | HK$759.13M | -3.1x | -0.06 | HK$1.40 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Emperor Capital | Hong Kong | Financial | Investment Banking & Investment Services | -14.8% | HK$357.26M | 5.3x | 0.04 | HK$0.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Capital Estate | Hong Kong | Financial | Investment Banking & Investment Services | -15.2% | HK$64.13M | 11.3x | 0.1 | HK$0.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galaxy Entertainment Group | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -15.9% | HK$137.72B | 16.5x | 0.01 | HK$31.50 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49% Upside | Upgrade to Pro+ | |
Melco Int Development | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -17.2% | HK$5.28B | -5x | -0.07 | HK$4.19 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
E Station Green Tech | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -17.5% | HK$17.04M | 0.3x | 0 | HK$0.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | -18.8% | HK$260.45M | -0.4x | -0.15 | HK$2.94 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Holly Futures Co | Hong Kong | Financial | Investment Banking & Investment Services | -19.1% | HK$2.67B | 108.4x | 1.23 | HK$2.65 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT Capital | Hong Kong | Financial | Investment Holding Companies | -19.4% | HK$147.71M | -18x | -0.3 | HK$0.05 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Graphene | Hong Kong | Real Estate | Real Estate Operations | -23.9% | HK$400.22M | 21x | 0.44 | HK$0.06 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | -24.3% | HK$1.03B | -5.9x | 0.75 | HK$0.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | -25.7% | HK$13.19B | -0.3x | -1.4 | HK$123.90 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.1% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | -26.3% | HK$12.28B | -5.5x | 0.4 | HK$12.32 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ARTA TechFin | Hong Kong | Financial | Investment Banking & Investment Services | -26.5% | HK$800.01M | -18.5x | -0.32 | HK$0.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CL | Hong Kong | Financial | Investment Banking & Investment Services | -32.2% | HK$94.60M | 3.9x | 0.02 | HK$0.04 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |